Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Vemurafenib can treat melanoma and Erdheim Chester Disease.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：7
Suitable for treating adult patients with metastatic non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：6
Alectinib treatment for non-small cell lung cancer.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：18
Overactive bladder (OAB)【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
Ibrutinib for the treatment of Chronic Lymphatic Leukemia【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：26
Afatinib can be used to treat Non Small Cell Lung Cancer.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：9
Tragliptin is suitable for type 2 diabetes.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：7
Fezolinetant is indicated for the treatment of vasomotor symptoms due to menopause.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：18
STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：6
Tofacitinib is indicated for the treatment of adult patients with rheumatoid arthritis.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：13
Used in combination with other antihypertensive drugs for the treatment of hypertension.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
Used for treating advanced renal cell carcinoma following failure of a prior systemic therapy.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：13
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
